Gaertner Susanne, de Graaf Katrien L, Greve Bernhard, Weissert Robert
Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Neurology. 2004 Dec 28;63(12):2381-3. doi: 10.1212/01.wnl.0000147259.34163.33.
Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.
通过酶联免疫吸附测定法（ELISA）检测了多发性硬化症（MS）患者和对照组中针对天然糖基化髓鞘少突胶质细胞糖蛋白（MOG）的抗体。在首次脱髓鞘事件期间，抗MOG IgM抗体升高。与缓解期患者和健康对照组相比，复发期患者以及继发慢性进展型MS患者体内发现了更高水平的MOG特异性IgG抗体。针对天然MOG的抗体可能是MS的一种潜在生物标志物。
